INTRODUCTION:
Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is the cause of Coronavirus Disease 2019 (COVID-19), which has spread to many nations and seriously harmed human health and the medical system1. 1–5. As of December 20, 2021, the WHO had documented 5351,812 deaths and 273,900,334 confirmed cases of COVID-19. According to https://covid19.who.int/, there are 112 nations with more than 100,000 COVID-19 infections and 40 countries with more than one million confirmed cases.2 Compared to DNA viruses, RNA viruses mutate more frequently. (3) Like other RNA viruses, SARS-CoV-2 has a high adaptive mutation ratewhen it adapts to new human hosts because of its larggenome (~30 kb) and low-fidelity RNA-dependent RNA polymerase (RdRp). 6, 7 January through September of 2021
Fig. 01 Alpha, Beta, Gamma, Delta Omicron
Symptoms and Causes:
Following the release of preliminary data indicating that the majority of cases of the novel omicron variation were associated with cold-like symptoms, the UK government has been encouraged to revise its list of symptoms for COVID-19.3 Runny nose, headache, weariness (either mild or severe), sneezing, and sore throat were the top five symptoms reported in the app for omicron infection, according to data released on December 16 by the Covid Symptoms Study1, which was conducted by the health science business Zoe and King's College London. Since London has a higher prevalence of omicron than other regions of the UK, it was chosen for this initial investigation based on positive cases.4
He said, "The government's messaging on this is just unclear. "I believe that most people are aware of the symptoms of a cold. London data were taken from a week in which delta was dominant (a sample of 363 cases from 3-10 October 2021) and compared with the most recent data (847 cases from 3-10 December 2021). This was done in order to compare delta and omicron. Three days after testing, there were no discernible differencesbetween delta and omicron in the early symptoms, according to this preliminary analysis.
Treatment:
Acetaminophen is used.5
Mechanism of Action:
One of the most popular over-the-counter analgesic and antipyretic medications is paracetamol, sometimes known as paracetamol or N-acetyl para-aminophenol (APAP).6 Since it inhibits the cyclooxygenase (COX) pathways, it has historically been classified as an NSAID, even though its precise mode of action is still unknown.7 In Acetaminophen has the same analgesic and antipyretic effects as NSAIDs. Acetaminophen, however, does not have any peripheral anti-inflammatory effects, according to research.8 In the central nervous system, but not in peripheral tissues, acetaminophen may inhibit the COX pathway.9 Furthermore, it seems that paracetamol lowers the activity of COX through a different mechanism than binding to the active site of either the COX-1 or COX-2 enzymes. 10 Additionally, paracetamol has been proposed to inhibit COX-1's splice variant, also known as COX-3; however, this has not been confirmed in human.11
Nevertheless, acetaminophen's inhibition of the COX pathway activity is hypothesised to prevent prostaglandin synthesis in the central nervous system, which accounts for the drug's analgesic and antipyretic effects.12 The central nervous system's (CNS) descending serotonergic pathways may be stimulated, which would account for the analgesic effects.13 According to some studies, acetaminophen or one of its metabolites, like AM 404, may also activate the cannabinoid system by preventing the uptake or breakdown of anandamide and 2-arachidonoylglycerol, which may help explain some of the analgesic effects of the drug .
Fig.02.Pathway of Prostaglandin
Administration:
It is possible to give acetaminophen intravenously (IV), rectally, or orally.14
Oral: We offer paracetamol in tablet, capsule, syrup, oral solution, and suspension forms for your convenience.
Rectal: Adult and paediatric patient populations can get acetaminophen as a rectal suppository.
Intravenous: Acetaminophen is also available as an IV infusion.15
Adverse Effect:
Hypersensitivity reactions and skin rashes Nephrotoxicity (increases in creatinine and BUN) Haematological conditions: pancytopenia, leukopenia, neutropenia, and anaemia Electrolyte and metabolic Lower blood bicarbonate levels Reduced calcium and sodium concentrations An excessive amount of ammone Overexposure to chlorine elevated uric acid elevated blood glucose elevated levels of alkaline phosphatase and bilirubin Adverse effects of intravenous acetaminophen include abdominal pain, nausea, vomiting, constipation, and pruritus. Hypersensitivity, anaphylactic reactions, and severe, potentially fatal skin underway.16 Compared to the Delta variant; this new variant is two to three times more contagious. 1109 of the 14,606 non-household contacts of reactions are uncommon but severe side effects. These include Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, and toxic epidermal necrolysis.
Prevention of omicron:
A worldwide epidemic of SARS-CoV-2 cases linked to the Omicron variant is currently people with the Omicron variant and 2922 of the 102,997 non-household contacts of people with the Delta variant, respectively, developed infection, according to a UK report (7.6% vs. 2.8%, respectively; adjusted odds ratio [OR], 2.63 [95% CI, 2.43-2.84]).1.18 In addition to causing a spike in infections in the community, the Omicron variant's increased contagiousness is also increasing transmissions in hospitals. In England, the final week of December 2021.19
Mandate Supplemental Doses:
Prior to Omicron becoming the predominant variant, studies found that individuals who have received vaccinations are half as likely to spread SARS-CoV-2 to others and two-thirds less likely to carry the virus than those who have not received vaccinations .Booster doses are necessary to enhance protection, though, because the Omicron variant is somewhat resistant to the current vaccinations.20 In the UK, a case-control study comparing 760 647 symptomatic Omicron variant-infected individuals to symptomatic individuals with negative tests revealed that, at 6 months, two doses of the messenger RNA vaccine reduced the likelihood of symptomatic illness by only 6% (OR, 0.94; 95% CI, 0.92-0.95).On the other hand, 3 booster doses raised protection against symptomatic disease to 68% (OR, 0.32; 95% CI, 0.31-0.33). The efficacy of boosters does diminish with time.21
Test more often:
Only a mild recommendation for SARS-CoV-2 admission testing at the time of hospital admission is made by the US Centres for Disease Control and Prevention.22 Nonetheless, the pretest probability of recently admitted asymptomatic patients being silent SARS-CoV-2 carriers is higher than ever due to the Omicron variant's surge in the community. 282 of 2960 asymptomatic patients (9.5%) admitted during the final week of 2021 in a large Massachusetts hospital system tested positive for SARS-CoV-2. Within-facility transmission is a persistent threat if potentially infectious SARS-CoV-2 carriers are not identified and isolated.23
Adopt a universal N95 respirator policy:
Depending on the fit of the mask, surgical and procedural masks can reduce viral exposure by an estimated 40% to 60%. 5, 6 If both participants the risk depends on the infectious dose of transmission 4 The risk of transmission increases with increased viral exposure. On the other hand, actions that lessen viral exposure lower the chance of transmission.in an interaction are wearing masks, the reduction in exposure is multiplied. 24 Wearing a mask is clearly linked to a lower risk of transmission, but it does not completely eliminate it. 25 Transmissions from masked clinicians to patients, from unmasked patients to clinicians, and from mutually masked patients and clinicians after prolonged interactions were well-documented even prior to the Omicron variant.7. Notwithstanding universal mask - wearing policies, outbreaks have also been reported in numeroushospitals.26
CONCLUSION:
As the world enters the fourth-year post-pandemic, the WHO said that COVID-19 remains a global health emergency. However, the world is transitioning into a new phase in which hospitalizations are reduced, and the number of deaths due to COVID has fallen to an ultimate low. On the other hand, as the Omicron sub-variants continue to predominate, their potency can decline and eventually become comparable to seasonal influenza, where the disease persists with milder symptoms. Moreover, the emergence of “layered immunity” as a result of reinfection should allow us to be better prepared for the next dominant strain. Monitoring of viral RNA, COVID-treatment drugs, and other pharmaceuticals in wastewater samples over a period of ~20 months in Suffolk County, NY, revealed that viral gene copies, across different variant prevailing periods, reflected the time series of COVID-19 confirmed cases in the sewer catchment area with a calculated lead time of 3–4 days. Antiviral drugs and their metabolites were detected with varying frequencies in wastewater samples. The rationale for monitoring COVID-19 treatment drugs in wastewater was to understand treatment of patients in the community. However, the stability of these drugs was low in wastewater and, hence, suggested that these drugs were not ideal biomarkers. However, acetaminophen (OTC) and desethyl hydroxychloroquine were significant correlated with the viral concentrations in wastewater and acetaminophen was also correlated with the prevalence of COVID-19 in the community. Acetaminophen exhibited a short-to-non-existent lead time (0-to-2 days) ahead of the virus and reported cases, which agreed with the symptom progression of COVID-19. Acetaminophen is abundant in wastewater and can be analyzed with minimum sample preparation compared to viral RNA analysis. Since acetaminophen and other similar OTC drugs are not specific to COVID treatment, their variations in wastewater may inform important changes in population health within the sewershed.
REFERENCES:
1. Feng W, Zong W, Wang F, Ju S. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review. Molecular Cancer. 2020 Dec; 19(1):1-4.
2. Saied AA, Metwally AA, Madkhali NA, Haque S, Dhama K. Egypt's COVID-19 recent happenings and perspectives: a mini-review. Frontiers in Public Health. 2021 Aug 16; 9:696082.
3. Drake JW, Holland JJ. Mutation rates among RNA viruses. Proceedings of the National Academy of Sciences. 1999 Nov 23; 96(24): 13910-3.
4. Ferreira C, Doursout MF, Balingit JS. Coronavirus Pandemics. In2000 Years of Pandemics: Past, Present, and Future. 2023 Feb 9 (pp. 143-222). Cham: Springer International Publishing.
5. Elliott P, Bodinier B, Eales O, Wang H, Haw D, Elliott J, Whitaker M, Jonnerby J, Tang D, Walters CE, Atchison C. Rapid increase in Omicron infections in England during December 2021: REACT-1 study. Science. 2022 Mar 25;375(6587):1406-11.
6. Chen G, Lu H. Oral high-dose acetylcysteine: Effective against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)? Drug Discoveries and Therapeutics. 2022 Jun 30; 16(3):139-41.
7. Ayoub SS. Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action. Temperature. 2021 Oct 2;8(4):351-71.
8. Ali KA, Maity A, Roy SD, Pramanik SD, Das PP, Shaharyar MA. Insight into the mechanism of steroidal and non-steroidal anti-inflammatory drugs. InHow Synthetic Drugs Work 2023 Jan 1 (pp. 61-94). Academic Press
9. .Przybyła GW, Szychowski KA, Gmiński J. Paracetamol–An old drug with new mechanisms of action. Clinical and Experimental Pharmacology and Physiology. 2021 Jan; 48(1):3-19.
10. Irinmwinuwa EO, Unekwe PC, Egba EU, Metu EC, Cherech NC. Acetaminophen: Ancient drug with a novel analgesic mechanism of action. World Journal of Advanced Research and Reviews. 2022; 16(1):580-9.
11. Emon NU, Alam S, Rudra S, Al Haidar IK, Farhad M, Rana ME, Ganguly A. Antipyretic activity of Caesalpiniadigyna (Rottl.) leaves extract along with phytoconstituent’s binding affinity to COX-1, COX-2, and mPGES-1 receptors: In vivo and in silico approaches. Saudi Journal of Biological Sciences. 2021 Sep 1; 28(9):5302-9.
12. Strillacci A. RNA Interference and cyclooxygenase-2 (COX-2) regulation in colon cancer cells.
13. Brennan K, Liu H. Acetaminophen. In First Aid Perioperative Ultrasound: Acute Pain Manual for Surgical Procedures 2023 Mar 3 (pp. 107-125). Cham: Springer International Publishing.
14. Bannister K, Dickenson AH. Central nervous system targets: supraspinal mechanisms of analgesia. Neurotherapeutics. 2020 Jul;17(3):839-45.
15. Ibrahim T, Gebril A, Nasr MK, Samad A, Zaki HA, Nasr Sr M. Unlocking the Optimal Analgesic Potential: A Systematic Review and Meta-Analysis Comparing Intravenous, Oral, and Rectal Paracetamol in Equivalent Doses. Cureus. 2023 Jul 14;15(7).
16. Trastullo R. Development of Innovative Formulations for Paediatric Use.
17. Cingi C, Muluk NB. Quick Guide to Anaphylaxis. Springer International Publishing; 2020
18. Klompas M, Karan A. Preventing SARS-CoV-2 transmission in health care settings in the context of the omicron variant. JAMA. 2022 Feb 15;327(7):619-20.
19. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, Louca P, May A, Figueiredo JC, Hu C, Molteni E. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. The Lancet. 2022 Apr 23; 399(10335):1618-24
20. Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review. Journal of Medical Virology. 2022 Jul; 94(7): 2969-76
21. Dudley MZ, Schwartz B, Brewer J, Kan L, Bernier R, Gerber JE, Ni HB, Proveaux TM, Rimal RN, Salmon DA. COVID-19 Vaccination Status, Attitudes, and Values among US Adults in September 2021. Journal of Clinical Medicine. 2022 Jun 28; 11(13): 3734.
22. Talbot TR, Hayden MK, Yokoe DS, Malani AN, Amer HA, Kalu IC, Logan LK, Moehring RW, Munoz-Price S, Palmore TN, Weber DJ. Asymptomatic screening for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) as an infection prevention measure in healthcare facilities: Challenges and considerations. Infection Control and Hospital Epidemiology. 2023 Jan;44(1):2-7
23. Sexton NR, Cline PJ, Gallichotte EN, Fitzmeyer E, Young MC, Janich AJ, Pabilonia KL, Ehrhart N, Ebel GD. SARS-CoV-2 entry into and evolution within a skilled nursing facility. Scientific Reports. 2023 Jul 19; 13(1): 11657.
24. Jefferson T, Dooley L, Ferroni E, Al-Ansary LA, van Driel ML, Bawazeer GA, Jones MA, Hoffmann TC, Clark J, Beller EM, Glasziou PP. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database of Systematic Reviews. 2023(1).
25. Howard J, Huang A, Li Z, Tufekci Z, Zdimal V, Van Der Westhuizen HM, Von Delft A, Price A, Fridman L, Tang LH, Tang V. Evidence reviews of face masks against COVID-19. Proceedings of the National Academy of Sciences. 2021 Jan 26; 118(4): e2014564118
26. Bielska IA, Manis DR, Schumacher C, Moore E, Lewis K, Agarwal G, Mondoux S, Jewett L, Speicher DJ, Liu RH, Leyenaar M. Health Sector Responses to the COVID-19 Pandemic in Ontario, Canada-January to May 2020. Public Health Management/Zdrowie Publicznei Zarzadzanie. 2020 Jan 1;18(1)
|
Received on 22.04.2024 Revised on 29.06.2024 Accepted on 13.08.2024 Published on 14.12.2024 Available online on December 05, 2024 Research J. Science and Tech. 2024; 16(4):299-303. DOI: 10.52711/2349-2988.2024.00042 ©A and V Publications All right reserved
|
|
|
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License. |
|
